title: Lack of α2C-Adrenoceptor Results in Contrasting Phenotypes of Long Bones and Vertebra and Prevents the Thyrotoxicosis-Induced Osteopenia.
abstract: A series of studies have demonstrated that activation of the sympathetic nervous system (SNS) causes osteopenia via β2-adrenoceptor (β2-AR) signaling. However, in a recent study, we found an unexpected and generalized phenotype of high bone mass in female mice with chronic sympathetic hyperactivity, due to double gene inactivation of adrenoceptors that negatively regulate norepinephrine release, α2A-and α2C-AR (α2A/2C-AR-/-). These findings suggest that β2-AR is not the single adrenoceptor involved in bone turnover regulation and show that α2-AR signaling may also mediate the SNS actions in the skeleton. In addition, we found that α2A/2C-AR-/- animals are resistant to the thyrotoxicosis-induced osteopenia, suggesting that thyroid hormone (TH), when in supraphysiological levels, interacts with the SNS to control bone mass and structure, and that this interaction may also involve α2-AR signaling. In the present study, to further investigate these hypotheses and to discriminate the roles of α2-AR subtypes, we have evaluated the bone phenotype of mice with the single gene inactivation of α2C-AR subtype, which mRNA expression was previously shown to be down regulated by triiodothyronine (T3). A cohort of 30 day-old female α2CAR-/- mice and their wild-type (WT) controls were treated with a supraphysiological dose of T3 for 30 or 90 days, which induced a thyrotoxic state in both mouse lineages. The micro-computed tomographic (μCT) analysis showed that α2C-AR-/- mice present lower trabecular bone volume (BV/TV) and number (Tb.N), and increased trabecular separation (Tb.Sp) in the femur compared with WT mice; which was accompanied by decreased bone strength (determined by the three-point bending test) in the femur and tibia. The opposite was observed in the vertebra, where α2C-AR-/- mice show increased BV/TV, Tb.N and trabecular thickness (Tb.Th), and decreased Tb.Sp, compared with WT animals. In spite of the contrasting bone phenotypes of the femur and L5, thyrotoxicosis negatively regulated most of the micro architectural features of the trabecular bone in both skeletal sites of WT, but not of α2C-AR-/- mice. T3 treatment also decreased biomechanical properties (maximum load and ultimate load) in the femur and tibia of WT, but not of knockout mice. The mRNA expression of osteocalcin, a marker of mature osteoblasts, and tartrate-resistant acid phosphatase, which is expressed by osteoclasts and is involved in collagen degradation, was increased by T3 treatment only in WT, and not in α2C-AR-/- mice. Altogether, these findings suggest that α2C-AR subtype mediates the effects of the SNS in the bone in a skeletal site-dependent manner, and that thyrotoxicosis depends on α2C-AR signaling to promote bone loss, which sustains the hypothesis of a TH-SNS interaction to modulate bone remodeling and structure.
authors.affiliation: Department of Anatomy, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
authors.forename: Marilia Bianca
authors.initials: MB
authors.lastname: Cruz Grecco Teixeira
authors.affiliation: Department of Anatomy, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
authors.forename: Gisele Miyamura
authors.initials: GM
authors.lastname: Martins
authors.affiliation: Department of Anatomy, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
authors.forename: Manuela
authors.initials: M
authors.lastname: Miranda-Rodrigues
authors.affiliation: Department of Anatomy, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
authors.forename: Iasmin Ferreira
authors.initials: IF
authors.lastname: De Araújo
authors.affiliation: RDODiagnosticos Medicos, Sao Paulo, Brazil.
authors.forename: Ricardo
authors.initials: R
authors.lastname: Oliveira
authors.affiliation: Departament of Biodinamic of Human Body Moviment, School of Physical Education and Sport, University of Sao Paulo, Sao Paulo, Brazil.
authors.forename: Patrícia Chakur
authors.initials: PC
authors.lastname: Brum
authors.affiliation: Department of Anatomy, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
authors.forename: Cecilia Helena
authors.initials: CH
authors.lastname: Azevedo Gouveia
mesh_terms: D000818:Animals; D001696:Biomechanical Phenomena; D001851:Bone Diseases, Metabolic / Q000097:blood / Q000209:etiology*; D016723:Bone Remodeling; D005260:Female; D005269:Femur / Q000378:metabolism / Q000503:physiopathology; D015870:Gene Expression; D018345:Mice, Knockout; D010641:Phenotype; D018341:Receptors, Adrenergic, alpha-2 / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction; D013131:Spine / Q000378:metabolism / Q000503:physiopathology; D013971:Thyrotoxicosis / Q000097:blood / Q000150:complications* / Q000235:genetics; D013974:Thyroxine / Q000097:blood; D013977:Tibia / Q000378:metabolism / Q000503:physiopathology; D014284:Triiodothyronine / Q000097:blood
chemical_list: D018341:Receptors, Adrenergic, alpha-2; D014284:Triiodothyronine; D013974:Thyroxine
references.citation: Mol Endocrinol. 2007 May;21(5):1095-107
references.pmid: 17327419
references.citation: Autoimmunity. 2008 Apr;41(3):218-23
references.pmid: 18365835
references.citation: Int J Mol Med. 2013 Jun;31(6):1457-62
references.pmid: 23588610
references.citation: Pharmacol Ther. 2004 Jan;101(1):65-74
references.pmid: 14729393
references.citation: J Bone Miner Res. 1997 Dec;12(12):2098-107
references.pmid: 9421243
references.citation: J Clin Endocrinol Metab. 1994 Apr;78(4):955-9
references.pmid: 8157727
references.citation: Trends Endocrinol Metab. 2012 Apr;23(4):155-62
references.pmid: 22169753
references.citation: Calcif Tissue Int. 2009 Apr;84(4):324-33
references.pmid: 19280098
references.citation: Acta Pathol Microbiol Scand A. 1978 Jan;86(1):56-62
references.pmid: 636889
references.citation: Arch Intern Med. 1985 May;145(5):883-6
references.pmid: 3838875
references.citation: Cell. 2002 Nov 1;111(3):305-17
references.pmid: 12419242
references.citation: Am J Physiol Endocrinol Metab. 2014 Aug 15;307(4):E408-18
references.pmid: 25005498
references.citation: J Cell Mol Med. 2015 Jul;19(7):1520-9
references.pmid: 25818344
references.citation: Endocrinology. 2001 Aug;142(8):3546-53
references.pmid: 11459801
references.citation: J Musculoskelet Neuronal Interact. 2008 Apr-Jun;8(2):94-104
references.pmid: 18622078
references.citation: Arch Intern Med. 1986 Jan;146(1):48-53
references.pmid: 3510598
references.citation: J Cell Biochem. 2015 Nov;116(11):2476-83
references.pmid: 25864714
references.citation: N Engl J Med. 1976 Feb 19;294(8):431-3
references.pmid: 1246310
references.citation: Acta Endocrinol (Copenh). 1977 Jul;85(3):515-25
references.pmid: 577336
references.citation: Front Physiol. 2014 Dec 05;5:475
references.pmid: 25538628
references.citation: Eur Thyroid J. 2013 Mar;2(1):3-13
references.pmid: 24783033
references.citation: Cell Tissue Res. 2006 Nov;326(2):541-51
references.pmid: 16896948
references.citation: Br J Pharmacol. 2001 Feb;132(4):925-33
references.pmid: 11181434
references.citation: Bone. 2010 Jan;46(1):72-80
references.pmid: 19781675
references.citation: Brain Res. 2010 Aug 6;1347:65-70
references.pmid: 20553874
references.citation: Med Sci Sports Exerc. 2005 Sep;37(9):1493-501
references.pmid: 16177600
references.citation: Anat Rec. 1995 Feb;241(2):284-7
references.pmid: 7710144
references.citation: Eur J Endocrinol. 1996 May;134(5):655-9
references.pmid: 8664988
references.citation: Calcif Tissue Int. 2014 Jan;94(1):140-51
references.pmid: 23765388
references.citation: Mol Endocrinol. 2013 Dec;27(12):2055-65
references.pmid: 24176915
references.citation: J Biol Chem. 2005 Aug 26;280(34):30192-200
references.pmid: 15961387
references.citation: J Bone Miner Res. 2011 Mar;26(3):591-603
references.pmid: 20814988
references.citation: Int J Endocrinol. 2013;2013:638727
references.pmid: 23970897
references.citation: J Bone Miner Res. 2007 Apr;22(4):578-88
references.pmid: 17243867
references.citation: J Clin Invest. 1956 Aug;35(8):874-87
references.pmid: 13345889
references.citation: Metab Bone Dis Relat Res. 1981;3(3):181-5
references.pmid: 7347794
references.citation: Endocrinology. 2014 Aug;155(8):2747-50
references.pmid: 25036648
references.citation: J Bone Miner Res. 2004 Oct;19(10):1607-11
references.pmid: 15355554
references.citation: Nouv Presse Med. 1982 Mar 20;11(13):989-91
references.pmid: 7070987
references.citation: Acta Pathol Microbiol Scand A. 1977 Mar;85A(2):141-50
references.pmid: 848285
references.citation: Bone. 1985;6(6):421-8
references.pmid: 4096878
references.citation: J Clin Invest. 1997 Feb 1;99(3):391-5
references.pmid: 9022071
references.citation: Nature. 2005 Mar 24;434(7032):514-20
references.pmid: 15724149
references.citation: J Auton Nerv Syst. 1988 Dec;25(2-3):119-25
references.pmid: 2906951
references.citation: Circulation. 2002 Nov 5;106(19):2491-6
references.pmid: 12417548
references.citation: Biol Cell. 2004 Jun;96(5):343-8
references.pmid: 15207902
references.citation: Trends Endocrinol Metab. 2003 Oct;14(8):356-64
references.pmid: 14516933
references.citation: Neuroscience. 2002;109(4):819-26
references.pmid: 11927164
references.citation: Int J Adolesc Med Health. 2002 Jul-Sep;14(3):235-44
references.pmid: 12467198
references.citation: PLoS One. 2013;8(7):e69067
references.pmid: 23935926
references.citation: N Engl J Med. 2010 Jan 28;362(4):361-2
references.pmid: 20107223
references.citation: Bone. 1994 Mar-Apr;15(2):199-202
references.pmid: 8086238
references.citation: J Clin Invest. 1991 Jan;87(1):125-32
references.pmid: 1985090
references.citation: Endocrinology. 1979 Jul;105(1):80-5
references.pmid: 446419